VistaGen Therapeutics Stock Discussion

$VistaGen Therapeutics (VTGN.US)$
Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder
Friday, 10th January at 8:30 am
All planned clinical studies in fasedienol U.S. registration-directed Phase 3 program for the acute treatment of social anxiety disorder are underway
Vistagen (NASDAQ: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in ...

$VistaGen Therapeutics (VTGN.US)$
500k shares buy usd3!!

$VistaGen Therapeutics (VTGN.US)$
Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Vistagen (Nasdaq: VTGN) has initiated the PALISADE-4 Phase 3 trial of fasedienol, an investigational neuroactive pherine nasal spray for the acute treatment of social anxiety disorder (SAD). This marks a significant milestone in the company's registration-directed PALISADE Phase 3 program. Fasedienol is designed for non-systemic, rapid activation of no...

$VistaGen Therapeutics (VTGN.US)$
3.28 buy 52k big fish

$VistaGen Therapeutics (VTGN.US)$ Reuters· just
Vistagen Broadens Ph80 Global Intellectual Property Portfolio With New Patents for the Treatment of Migraine

$VistaGen Therapeutics (VTGN.US)$
VistaGen Therapeutics GAAP EPS of -$1.52 misses by $1.16, revenue of $1.06M beats by $0.86M
Jun. 11, 2024 4:23 PM ETVistagen Therapeutics, Inc. (VTGN) StockBy: Mary Christine Joy, SA News Editor
VistaGen Therapeutics press release (NASDAQ:VTGN): Q4 GAAP EPS of -$1.52 misses by $1.16.
Revenue of $1.06M (vs. -$0.23M last year)  beats by $0.86M.
Shares +0.8%.
Registration-directed fasedienol PALISADE Phase 3 program for the acute treatment of social anxiety disorder...